Vi-CRM197 vaccine

BIOLOGICAL2 trials

Sponsors

Novartis

Conditions

Typhoid Fever

Phase 2

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants

CompletedNCT01229176

NovartisTyphoid Fever

Start: 2011-03-31End: 2012-06-30Updated: 2014-05-01

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

CompletedNCT01437267

NovartisTyphoid Fever

Start: 2011-10-31End: 2012-08-31Updated: 2014-04-10

Related Papers

Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.

2013-11-2899 citations